Share on StockTwits

Cytokinetics (NASDAQ:CYTK) Director L Patrick Gage acquired 10,850 shares of Cytokinetics stock in a transaction dated Friday, May 9th. The shares were purchased at an average price of $4.09 per share, with a total value of $44,376.50. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $40,900. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Cytokinetics (NASDAQ:CYTK) traded up 1.87% on Monday, hitting $4.36. The stock had a trading volume of 1,234,878 shares. Cytokinetics has a 52 week low of $3.96 and a 52 week high of $14.28. The stock has a 50-day moving average of $7.87 and a 200-day moving average of $7.86. The company’s market cap is $159.6 million.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.07. The company had revenue of $8.00 million for the quarter, compared to the consensus estimate of $7.69 million. Analysts expect that Cytokinetics will post $-1.20 EPS for the current fiscal year.

CYTK has been the subject of a number of recent research reports. Analysts at Canaccord Genuity reiterated a “buy” rating on shares of Cytokinetics in a research note on Thursday. They now have a $8.00 price target on the stock, down previously from $9.00. Finally, analysts at Needham & Company LLC cut their price target on shares of Cytokinetics from $25.00 to $15.00 in a research note on Monday, April 28th. They now have a “buy” rating on the stock. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Cytokinetics presently has a consensus rating of “Buy” and a consensus target price of $12.00.

Cytokinetics, Incorporated (NASDAQ:CYTK) is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.